Propranolol (PPN) is widely used in children to treat various cardiovascular diseases. The availability of a suitable PPN solution should avoid recourse to extemporaneous preparations of unknown/limited stability, as commonly made in hospital pharmacies. However, the development of pediatric PPN solutions is hindered by their instability to light and stability at pH 3, bitter taste, and the need to improve palatability and avoid co-solvents, flavoring agents, or preservatives that are potentially toxic. In this study, cyclodextrin (CD) complexation has been exploited to develop a safe, stable, and palatable oral pediatric solution of PPN. An initial screening among various CDs allowed us to select HP CD for its good complexing ability and no toxicity. Drug-HP CD physical mixtures or co-ground systems (1:1 or 1:2 mol:mol) were used to prepare 0.2% w/v drug solutions. Photo stability studies evidenced the protective effect of HP CD, revealing a reduction of up to 75% in the drug degradation rate after 1 h of exposure to UV radiation. Storage stability studies showed unchanged physical–chemical properties and almost constant drug concentration after 6 months and under accelerated conditions (40 °C), despite the less aggressive pH ( 5.5) of the solution. The electronic tongue test proved that the HP CD taste-masking properties improved the formulation palatability, with a 30% reduction in drug bitterness.

Development of a Hydroxypropyl-β-Cyclodextrin-Based Liquid Formulation for the Oral Administration of Propranolol in Pediatric Therapy / M. Cirri, P. Mura, S. Benedetti, S. Buratti. - In: PHARMACEUTICS. - ISSN 1999-4923. - 15:9(2023), pp. 2217.1-2217.16. [10.3390/pharmaceutics15092217]

Development of a Hydroxypropyl-β-Cyclodextrin-Based Liquid Formulation for the Oral Administration of Propranolol in Pediatric Therapy

S. Benedetti
Penultimo
;
S. Buratti
Ultimo
2023

Abstract

Propranolol (PPN) is widely used in children to treat various cardiovascular diseases. The availability of a suitable PPN solution should avoid recourse to extemporaneous preparations of unknown/limited stability, as commonly made in hospital pharmacies. However, the development of pediatric PPN solutions is hindered by their instability to light and stability at pH 3, bitter taste, and the need to improve palatability and avoid co-solvents, flavoring agents, or preservatives that are potentially toxic. In this study, cyclodextrin (CD) complexation has been exploited to develop a safe, stable, and palatable oral pediatric solution of PPN. An initial screening among various CDs allowed us to select HP CD for its good complexing ability and no toxicity. Drug-HP CD physical mixtures or co-ground systems (1:1 or 1:2 mol:mol) were used to prepare 0.2% w/v drug solutions. Photo stability studies evidenced the protective effect of HP CD, revealing a reduction of up to 75% in the drug degradation rate after 1 h of exposure to UV radiation. Storage stability studies showed unchanged physical–chemical properties and almost constant drug concentration after 6 months and under accelerated conditions (40 °C), despite the less aggressive pH ( 5.5) of the solution. The electronic tongue test proved that the HP CD taste-masking properties improved the formulation palatability, with a 30% reduction in drug bitterness.
propranolol; pediatric solutions; hydroxypropyl-β-cyclodextrin; photo stability; storage stability; electronic tongue
Settore CHIM/08 - Chimica Farmaceutica
2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
pharmaceutics-2023.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 3.21 MB
Formato Adobe PDF
3.21 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/995448
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact